Clinical Trials Browser

OTHER × Interventional × Castleman Disease × Clear all

Castleman Disease, Histiocytosis, Langerhans-Cell, Histiocytosis, Non-Langerhans-Cell

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT02080416 2016-06-10

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Phase EARLY_PHASE1 Terminated

1 enrolled

GastrointestinalHead & NeckLymphoidSarcoma

Castleman Disease, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Nasopharyngeal Neoplasms, Neoplasms, Sarcoma, Sarcoma, Kaposi, Stomach Neoplasms

Clinical Trials

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors